Cargando…
Can a Positive Allosteric Modulation of GABAergic Receptors Improve Motor Symptoms in Patients with Parkinson's Disease? The Potential Role of Zolpidem in the Treatment of Parkinson's Disease
At present, patients with advanced Parkinson's disease (PD) are unsatisfactorily controlled by currently used anti-Parkinsonian dopaminergic drugs. Various studies suggest that therapeutic strategies based on nondopaminergic drugs might be helpful in PD. Zolpidem, an imidazopyridine widely used...
Autores principales: | Daniele, Antonio, Panza, Francesco, Greco, Antonio, Logroscino, Giancarlo, Seripa, Davide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4886078/ https://www.ncbi.nlm.nih.gov/pubmed/27293955 http://dx.doi.org/10.1155/2016/2531812 |
Ejemplares similares
-
Genetic Profile, Environmental Exposure, and Their Interaction in Parkinson's Disease
por: Polito, Letizia, et al.
Publicado: (2016) -
Parkinson's disease motor symptoms rescue by CRISPRa‐reprogramming astrocytes into GABAergic neurons
por: Giehrl‐Schwab, Jessica, et al.
Publicado: (2022) -
Nutrition, frailty, and Alzheimer's disease
por: Panza, Francesco, et al.
Publicado: (2014) -
Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer's Disease
por: Panza, Francesco, et al.
Publicado: (2016) -
Molecular Imaging of the GABAergic System in Parkinson’s Disease and Atypical Parkinsonisms
por: Terkelsen, Miriam H., et al.
Publicado: (2022)